In Brief: The Liposome Company's TLC A-60
The Liposome Company's TLC A-60: Wyeth-Ayerst will return all rights to the liposomal vaccine adjuvant, which Wyeth had been using in the development of an influenza vaccine that has reached Phase II, TLC reports March 14. TLC says it has not seen the Phase II results but expects to seek another corporate partner. The company licensed TLC A-60 to Wyeth in 1992...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth